Augmented Intelligence: The next step in AI-driven drug research
When we hear the term AI most of us think ‘Artificial Intelligence. More recently, however, more and more people are using other terms like ‘Augmented’ or ‘Amplified’ intelligence.
Gartner defines this as follows: “Augmented intelligence is a design pattern for a human-centred partnership model of people and artificial intelligence (AI) working together to enhance cognitive performance, including learning, decision making and new experiences.”
This re-interpretation of the ‘A’ in ‘AI’ signals a key change in perspective that focuses more on the human-machine interaction. The combination plays to their own strengths to achieve greater impact.
From the Euretos perspective, defining AI as Augmented Intelligence represents how we apply AI in enabling data-driven disease and drug research.
For instance, in our projects, our team of biologists interpret the outcomes of our computational disease models. This interpretation is then shared with the disease experts on the customer side, and the feedback is fed back into the disease modelling. We are also in a unique position that our cloud AI Platform is directly available to our consultants and customers to help in the interpretation of results through prior knowledge from hundreds of databases and millions of publications and patents.
This iterative and interpretative process is key to maximising the impact of AI on the research results.
It is also becoming clear that some of the key technologies in which AI is applied are reaching maturity as defined by Gartner in their Hype Cycle:
Here we see that key AI technologies the Euretos uses, like a machine and deep learning, natural language processing and especially insight engines (our cloud AI platform), are moving from hype to productivity.
If you would like to know more about how we enable Augmented Intelligence in disease and drug research, please contact us, and we will be happy to tell you more about it!
This blog is based on the keynote that Euretos co-founder, Arie Baak, held for the AI in Drug Discovery conference on the 18th of May, 2021.
Subscribe to our mailing list and receive our quarterly updates!